EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKIs) remains the first-line therapeutic option for advanced non-small cell lung cancer (NSCLC) with EGFR mutation (3, 4).